The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CNS Specific Antisense Oligonucleotides Market Research Report 2024
Synopsis
Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing. Subsequent chemical modifications of antisense oligonucleotides were used to address issues such as off-target toxic effects and insufficient biological activity. These modifications led to an improved mechanism of antisense oligonucleotides and clinical trial design. This paved the way toward translating their use into therapies for various genetic and neurological conditions. Antisense oligonucleotides mediated therapies target the source of pathogenesis and have higher chance of success as compared to therapies that target downstream pathways. These are drugs for the treatment of central nervous system (CNS) disorders, as they have specific molecular targeting and extended pharmacological properties.
The global CNS Specific Antisense Oligonucleotides market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CNS Specific Antisense Oligonucleotides is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CNS Specific Antisense Oligonucleotides is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for CNS Specific Antisense Oligonucleotides in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of CNS Specific Antisense Oligonucleotides include Akcea Therapeutics, Inc., Ionis Pharmaceuticals Inc., Biogen Inc., Sarepta Therapeutics, Wave Life Sciences Ltd., Dynacure, ProQR Therapeutics N.V. and Stroke Therapeutic Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CNS Specific Antisense Oligonucleotides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CNS Specific Antisense Oligonucleotides.
Report Scope
The CNS Specific Antisense Oligonucleotides market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CNS Specific Antisense Oligonucleotides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CNS Specific Antisense Oligonucleotides companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Akcea Therapeutics, Inc.
Ionis Pharmaceuticals Inc.
Biogen Inc.
Sarepta Therapeutics
Wave Life Sciences Ltd.
Dynacure
ProQR Therapeutics N.V.
Stroke Therapeutic Inc.
Segment by Type
Polyneuropathy Treatment
Spinal Muscular Atrophy (SMA) Treatment
Huntington’s Disease Treatment
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CNS Specific Antisense Oligonucleotides companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing. Subsequent chemical modifications of antisense oligonucleotides were used to address issues such as off-target toxic effects and insufficient biological activity. These modifications led to an improved mechanism of antisense oligonucleotides and clinical trial design. This paved the way toward translating their use into therapies for various genetic and neurological conditions. Antisense oligonucleotides mediated therapies target the source of pathogenesis and have higher chance of success as compared to therapies that target downstream pathways. These are drugs for the treatment of central nervous system (CNS) disorders, as they have specific molecular targeting and extended pharmacological properties.
The global CNS Specific Antisense Oligonucleotides market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CNS Specific Antisense Oligonucleotides is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CNS Specific Antisense Oligonucleotides is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for CNS Specific Antisense Oligonucleotides in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of CNS Specific Antisense Oligonucleotides include Akcea Therapeutics, Inc., Ionis Pharmaceuticals Inc., Biogen Inc., Sarepta Therapeutics, Wave Life Sciences Ltd., Dynacure, ProQR Therapeutics N.V. and Stroke Therapeutic Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CNS Specific Antisense Oligonucleotides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CNS Specific Antisense Oligonucleotides.
Report Scope
The CNS Specific Antisense Oligonucleotides market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CNS Specific Antisense Oligonucleotides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CNS Specific Antisense Oligonucleotides companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Akcea Therapeutics, Inc.
Ionis Pharmaceuticals Inc.
Biogen Inc.
Sarepta Therapeutics
Wave Life Sciences Ltd.
Dynacure
ProQR Therapeutics N.V.
Stroke Therapeutic Inc.
Segment by Type
Polyneuropathy Treatment
Spinal Muscular Atrophy (SMA) Treatment
Huntington’s Disease Treatment
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CNS Specific Antisense Oligonucleotides companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Polyneuropathy Treatment
1.2.3 Spinal Muscular Atrophy (SMA) Treatment
1.2.4 Huntington’s Disease Treatment
1.3 Market by Application
1.3.1 Global CNS Specific Antisense Oligonucleotides Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CNS Specific Antisense Oligonucleotides Market Perspective (2019-2030)
2.2 CNS Specific Antisense Oligonucleotides Growth Trends by Region
2.2.1 Global CNS Specific Antisense Oligonucleotides Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 CNS Specific Antisense Oligonucleotides Historic Market Size by Region (2019-2024)
2.2.3 CNS Specific Antisense Oligonucleotides Forecasted Market Size by Region (2025-2030)
2.3 CNS Specific Antisense Oligonucleotides Market Dynamics
2.3.1 CNS Specific Antisense Oligonucleotides Industry Trends
2.3.2 CNS Specific Antisense Oligonucleotides Market Drivers
2.3.3 CNS Specific Antisense Oligonucleotides Market Challenges
2.3.4 CNS Specific Antisense Oligonucleotides Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CNS Specific Antisense Oligonucleotides Players by Revenue
3.1.1 Global Top CNS Specific Antisense Oligonucleotides Players by Revenue (2019-2024)
3.1.2 Global CNS Specific Antisense Oligonucleotides Revenue Market Share by Players (2019-2024)
3.2 Global CNS Specific Antisense Oligonucleotides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CNS Specific Antisense Oligonucleotides Revenue
3.4 Global CNS Specific Antisense Oligonucleotides Market Concentration Ratio
3.4.1 Global CNS Specific Antisense Oligonucleotides Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CNS Specific Antisense Oligonucleotides Revenue in 2023
3.5 CNS Specific Antisense Oligonucleotides Key Players Head office and Area Served
3.6 Key Players CNS Specific Antisense Oligonucleotides Product Solution and Service
3.7 Date of Enter into CNS Specific Antisense Oligonucleotides Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CNS Specific Antisense Oligonucleotides Breakdown Data by Type
4.1 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Type (2019-2024)
4.2 Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Type (2025-2030)
5 CNS Specific Antisense Oligonucleotides Breakdown Data by Application
5.1 Global CNS Specific Antisense Oligonucleotides Historic Market Size by Application (2019-2024)
5.2 Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America CNS Specific Antisense Oligonucleotides Market Size (2019-2030)
6.2 North America CNS Specific Antisense Oligonucleotides Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024)
6.4 North America CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CNS Specific Antisense Oligonucleotides Market Size (2019-2030)
7.2 Europe CNS Specific Antisense Oligonucleotides Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024)
7.4 Europe CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size (2019-2030)
8.2 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region (2019-2024)
8.4 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CNS Specific Antisense Oligonucleotides Market Size (2019-2030)
9.2 Latin America CNS Specific Antisense Oligonucleotides Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024)
9.4 Latin America CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size (2019-2030)
10.2 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024)
10.4 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Akcea Therapeutics, Inc.
11.1.1 Akcea Therapeutics, Inc. Company Detail
11.1.2 Akcea Therapeutics, Inc. Business Overview
11.1.3 Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Introduction
11.1.4 Akcea Therapeutics, Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.1.5 Akcea Therapeutics, Inc. Recent Development
11.2 Ionis Pharmaceuticals Inc.
11.2.1 Ionis Pharmaceuticals Inc. Company Detail
11.2.2 Ionis Pharmaceuticals Inc. Business Overview
11.2.3 Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Introduction
11.2.4 Ionis Pharmaceuticals Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.2.5 Ionis Pharmaceuticals Inc. Recent Development
11.3 Biogen Inc.
11.3.1 Biogen Inc. Company Detail
11.3.2 Biogen Inc. Business Overview
11.3.3 Biogen Inc. CNS Specific Antisense Oligonucleotides Introduction
11.3.4 Biogen Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.3.5 Biogen Inc. Recent Development
11.4 Sarepta Therapeutics
11.4.1 Sarepta Therapeutics Company Detail
11.4.2 Sarepta Therapeutics Business Overview
11.4.3 Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Introduction
11.4.4 Sarepta Therapeutics Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.4.5 Sarepta Therapeutics Recent Development
11.5 Wave Life Sciences Ltd.
11.5.1 Wave Life Sciences Ltd. Company Detail
11.5.2 Wave Life Sciences Ltd. Business Overview
11.5.3 Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Introduction
11.5.4 Wave Life Sciences Ltd. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.5.5 Wave Life Sciences Ltd. Recent Development
11.6 Dynacure
11.6.1 Dynacure Company Detail
11.6.2 Dynacure Business Overview
11.6.3 Dynacure CNS Specific Antisense Oligonucleotides Introduction
11.6.4 Dynacure Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.6.5 Dynacure Recent Development
11.7 ProQR Therapeutics N.V.
11.7.1 ProQR Therapeutics N.V. Company Detail
11.7.2 ProQR Therapeutics N.V. Business Overview
11.7.3 ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Introduction
11.7.4 ProQR Therapeutics N.V. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.7.5 ProQR Therapeutics N.V. Recent Development
11.8 Stroke Therapeutic Inc.
11.8.1 Stroke Therapeutic Inc. Company Detail
11.8.2 Stroke Therapeutic Inc. Business Overview
11.8.3 Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Introduction
11.8.4 Stroke Therapeutic Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024)
11.8.5 Stroke Therapeutic Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Polyneuropathy Treatment
Table 3. Key Players of Spinal Muscular Atrophy (SMA) Treatment
Table 4. Key Players of Huntington’s Disease Treatment
Table 5. Global CNS Specific Antisense Oligonucleotides Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global CNS Specific Antisense Oligonucleotides Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global CNS Specific Antisense Oligonucleotides Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global CNS Specific Antisense Oligonucleotides Market Share by Region (2019-2024)
Table 9. Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global CNS Specific Antisense Oligonucleotides Market Share by Region (2025-2030)
Table 11. CNS Specific Antisense Oligonucleotides Market Trends
Table 12. CNS Specific Antisense Oligonucleotides Market Drivers
Table 13. CNS Specific Antisense Oligonucleotides Market Challenges
Table 14. CNS Specific Antisense Oligonucleotides Market Restraints
Table 15. Global CNS Specific Antisense Oligonucleotides Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global CNS Specific Antisense Oligonucleotides Market Share by Players (2019-2024)
Table 17. Global Top CNS Specific Antisense Oligonucleotides Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CNS Specific Antisense Oligonucleotides as of 2023)
Table 18. Ranking of Global Top CNS Specific Antisense Oligonucleotides Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by CNS Specific Antisense Oligonucleotides Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players CNS Specific Antisense Oligonucleotides Product Solution and Service
Table 22. Date of Enter into CNS Specific Antisense Oligonucleotides Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CNS Specific Antisense Oligonucleotides Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global CNS Specific Antisense Oligonucleotides Revenue Market Share by Type (2019-2024)
Table 26. Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global CNS Specific Antisense Oligonucleotides Revenue Market Share by Type (2025-2030)
Table 28. Global CNS Specific Antisense Oligonucleotides Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global CNS Specific Antisense Oligonucleotides Revenue Market Share by Application (2019-2024)
Table 30. Global CNS Specific Antisense Oligonucleotides Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global CNS Specific Antisense Oligonucleotides Revenue Market Share by Application (2025-2030)
Table 32. North America CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country (2025-2030) & (US$ Million)
Table 47. Akcea Therapeutics, Inc. Company Detail
Table 48. Akcea Therapeutics, Inc. Business Overview
Table 49. Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Product
Table 50. Akcea Therapeutics, Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 51. Akcea Therapeutics, Inc. Recent Development
Table 52. Ionis Pharmaceuticals Inc. Company Detail
Table 53. Ionis Pharmaceuticals Inc. Business Overview
Table 54. Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Product
Table 55. Ionis Pharmaceuticals Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 56. Ionis Pharmaceuticals Inc. Recent Development
Table 57. Biogen Inc. Company Detail
Table 58. Biogen Inc. Business Overview
Table 59. Biogen Inc. CNS Specific Antisense Oligonucleotides Product
Table 60. Biogen Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 61. Biogen Inc. Recent Development
Table 62. Sarepta Therapeutics Company Detail
Table 63. Sarepta Therapeutics Business Overview
Table 64. Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Product
Table 65. Sarepta Therapeutics Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 66. Sarepta Therapeutics Recent Development
Table 67. Wave Life Sciences Ltd. Company Detail
Table 68. Wave Life Sciences Ltd. Business Overview
Table 69. Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Product
Table 70. Wave Life Sciences Ltd. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 71. Wave Life Sciences Ltd. Recent Development
Table 72. Dynacure Company Detail
Table 73. Dynacure Business Overview
Table 74. Dynacure CNS Specific Antisense Oligonucleotides Product
Table 75. Dynacure Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 76. Dynacure Recent Development
Table 77. ProQR Therapeutics N.V. Company Detail
Table 78. ProQR Therapeutics N.V. Business Overview
Table 79. ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Product
Table 80. ProQR Therapeutics N.V. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 81. ProQR Therapeutics N.V. Recent Development
Table 82. Stroke Therapeutic Inc. Company Detail
Table 83. Stroke Therapeutic Inc. Business Overview
Table 84. Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Product
Table 85. Stroke Therapeutic Inc. Revenue in CNS Specific Antisense Oligonucleotides Business (2019-2024) & (US$ Million)
Table 86. Stroke Therapeutic Inc. Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CNS Specific Antisense Oligonucleotides Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global CNS Specific Antisense Oligonucleotides Market Share by Type: 2023 VS 2030
Figure 3. Polyneuropathy Treatment Features
Figure 4. Spinal Muscular Atrophy (SMA) Treatment Features
Figure 5. Huntington’s Disease Treatment Features
Figure 6. Global CNS Specific Antisense Oligonucleotides Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global CNS Specific Antisense Oligonucleotides Market Share by Application: 2023 VS 2030
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. CNS Specific Antisense Oligonucleotides Report Years Considered
Figure 12. Global CNS Specific Antisense Oligonucleotides Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global CNS Specific Antisense Oligonucleotides Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global CNS Specific Antisense Oligonucleotides Market Share by Region: 2023 VS 2030
Figure 15. Global CNS Specific Antisense Oligonucleotides Market Share by Players in 2023
Figure 16. Global Top CNS Specific Antisense Oligonucleotides Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CNS Specific Antisense Oligonucleotides as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by CNS Specific Antisense Oligonucleotides Revenue in 2023
Figure 18. North America CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America CNS Specific Antisense Oligonucleotides Market Share by Country (2019-2030)
Figure 20. United States CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe CNS Specific Antisense Oligonucleotides Market Share by Country (2019-2030)
Figure 24. Germany CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific CNS Specific Antisense Oligonucleotides Market Share by Region (2019-2030)
Figure 32. China CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America CNS Specific Antisense Oligonucleotides Market Share by Country (2019-2030)
Figure 40. Mexico CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa CNS Specific Antisense Oligonucleotides Market Share by Country (2019-2030)
Figure 44. Turkey CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia CNS Specific Antisense Oligonucleotides Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Akcea Therapeutics, Inc. Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 47. Ionis Pharmaceuticals Inc. Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 48. Biogen Inc. Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 49. Sarepta Therapeutics Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 50. Wave Life Sciences Ltd. Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 51. Dynacure Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 52. ProQR Therapeutics N.V. Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 53. Stroke Therapeutic Inc. Revenue Growth Rate in CNS Specific Antisense Oligonucleotides Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
